Inflammatory bowel disease increases the risk of developing
colon cancer.
Interleukin (IL-) 37 is a fundamental inhibitor of innate immunity by reducing systemic and local
inflammation. IL-37
protein is expressed in healthy and diseased bowel and liver tissue. Here, we tested whether transgenic expression of human IL-37 protects
IL-10 deficient (IL-10KO) mice from chronic
colitis. IL-37tg mice were crossbred with IL-10KO mice. Homozygous IL-10KO/IL-37tg and IL10KO drank 2%
dextran sulfate sodium (DSS) in water for 5 days to induce mild
colitis. Colon
carcinogenesis was triggered by intragastric administration of
celecoxib. Endpoints were clinical parameters of
colitis,
cytokine responses in LPS-stimulated whole blood and explanted colon specimen and qPCR analysis of colon biopsies. Colon
inflammation and number of
adenoma-
carcinoma were analyzed by histology. During the DSS-induction phase IL-10KO and IL-10KO/IL-37tg mice had a similar
weight loss due to mild acute
colitis. From day 115 there was a significantly improved
weight gain in IL-10KO/IL37-tg mice, though colon length was similar. After ex vivo LPS stimulation whole blood of IL-10KO/IL-37tg compared to IL-10KO mice released less
IL-6,
IL-17, IFNγ, and TNFα and ex vivo colon cultures showed reduced
IL-6 production both indicative of reduced inflammatory conditions under the influence of IL-37. Six out of 10 IL-10KO mice developed colon
adenoma and
carcinoma. Only one
adenoma but no
carcinoma was detected in colons of IL-10KO/IL-37tg mice. In conclusion, IL-37 transgene expression protects IL-10KO mice from colon
carcinogenesis. It remains unclear whether IL-37 has direct
tumor suppressing properties.